JAMP Pharma Group is active in all sectors of the pharmaceutical industry with our JAMP Pharma generic products, our Orimed Pharma branded products, our Wampole and Laboratoire Suisse natural health products, and our Cosmetic Import beauty and personal care products.
JAMP Pharma Group has also made a recent major investment in biosimilars—one of the fastest growing markets in the industry—with the launch of its BIOJAMP division.
For nearly 35 years, we have been committed to supporting healthcare professionals so that they may focus on what matters most: the well-being of Canadians. We have made healthcare solutions more accessible and affordable for both patients and consumers.
As we look to the future, we are committed to ensuring that our diversified product portfolio remains accessible to all, while guaranteeing the most reliable supply in Canada.
Our divisions 6
JAMP Pharma Group receives Health Canada approval for Pr JAMP Dapagliflozin, a new generic alternative for the treatment of type 2 diabetes
The JAMP Pharma Group has received authorization to market Dapagliflozin, offering a more affordable alternative to the reference product Forxiga® (marketed by AstraZeneca Canada Inc.). The JAMP Pharma Group, a leader in product launches1, is expending its product line for the treatment of diabetes, bringing it closer to achieving its goal…
New launches, Press release
The JAMP Pharma Group launches Pr JAMP Apremilast, a new generic alternative for the treatment of plaque psoriasis and psoriatic arthritis
The JAMP Pharma Group launches Apremilast, a specialty generic, offering a more affordable alternative to the reference product Otezla® (marketed by Amgen Canada Inc.). The JAMP Pharma Group, a leader in product launches1, expands its line of specialty products, contributing to its ambition to offer healthcare professionals and patients services…